Rhenman & Partners Asset Management Ab Vertex Pharmaceuticals Inc Transaction History

Rhenman & Partners Asset Management Ab

$1.01 Billion
Q2 2024

A detailed history of Rhenman & Partners Asset Management Ab transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Rhenman & Partners Asset Management Ab holds 54,000 shares of VRTX stock, worth $27.9 Million. This represents 2.5% of its overall portfolio holdings.

Number of Shares

54,000

Previous 56,500 4.42%

Holding current value

$27.9 Million

Previous $23.6 Million 7.17%

% of portfolio

2.5%

Previous 2.31%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $982,025 - $1.21 Million	-2,500 Reduced 4.42%	54,000 $25.3 Million
Q1 2024 May 14, 2024	SELL	$407.69 - $446.08 $15.7 Million - $17.2 Million	-38,500 Reduced 40.53%	56,500 $23.6 Million
Q4 2023 Feb 13, 2024	BUY	$343.0 - $410.68 $6.35 Million - $7.6 Million	18,500 Added 24.18%	95,000 $38.7 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $14 Million - $15 Million	41,500 Added 118.57%	76,500 $26.6 Million
Q3 2023 Nov 09, 2023	SELL	$338.18 - $362.46 $9.64 Million - $10.3 Million	-28,500 Reduced 44.88%	35,000 $12.2 Million
Q2 2023 Aug 11, 2023	SELL	$314.42 - $351.91 $6.29 Million - $7.04 Million	-20,000 Reduced 23.95%	63,500 $22.3 Million
Q1 2023 May 11, 2023	BUY	$283.23 - $323.1 $991,305 - $1.13 Million	3,500 Added 4.38%	83,500 $26.3 Million
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $4.57 Million - $5.14 Million	-16,000 Reduced 16.67%	80,000 $23.1 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $273,830 - $305,530	1,000 Added 1.05%	96,000 $30 Million
Q2 2022 Aug 12, 2022	BUY	$234.96 - $292.55 $1.29 Million - $1.61 Million	5,500 Added 6.15%	95,000 $26.8 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $16.7 Million - $19.7 Million	-75,500 Reduced 45.76%	89,500 $23.4 Million
Q3 2021 Nov 12, 2021	SELL	$181.39 - $202.99 $9.23 Million - $10.3 Million	-50,897 Reduced 23.57%	165,000 $29.9 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $8.9 Million - $10.5 Million	47,476 Added 28.19%	215,897 $43.5 Million
Q1 2021 May 14, 2021	BUY	$207.02 - $241.31 $11.1 Million - $12.9 Million	53,421 Added 46.45%	168,421 $36.2 Million
Q4 2020 Jan 19, 2021	BUY	$207.01 - $276.09 $1.04 Million - $1.38 Million	5,000 Added 4.55%	115,000 $27.2 Million
Q3 2020 Oct 13, 2020	SELL	$255.65 - $303.1 $7.03 Million - $8.34 Million	-27,500 Reduced 20.0%	110,000 $29.9 Million
Q2 2020 Jul 16, 2020	BUY	$225.48 - $295.8 $5.07 Million - $6.66 Million	22,500 Added 19.57%	137,500 $39.9 Million
Q1 2020 Apr 16, 2020	SELL	$199.77 - $247.81 $8.99 Million - $11.2 Million	-45,000 Reduced 28.13%	115,000 $27.4 Million
Q4 2019 Jan 17, 2020	SELL	$166.71 - $223.91 $4.33 Million - $5.82 Million	-26,000 Reduced 13.98%	160,000 $35 Million
Q3 2019 Oct 16, 2019	BUY	$166.23 - $187.09 $127,664 - $143,685	768 Added 0.41%	186,000 $31.5 Million
Q2 2019 Jul 22, 2019	BUY	$164.61 - $190.37 $6.72 Million - $7.77 Million	40,832 Added 28.28%	185,232 $34 Million
Q1 2019 Apr 11, 2019	BUY	$163.73 - $194.7 $1.96 Million - $2.33 Million	11,975 Added 9.04%	144,400 $26.6 Million
Q4 2018 Feb 05, 2019	SELL	$151.91 - $192.21 $1.53 Million - $1.93 Million	-10,040 Reduced 7.05%	132,425 $21.9 Million
Q3 2018 Oct 03, 2018	SELL	$167.73 - $192.74 $2.1 Million - $2.42 Million	-12,535 Reduced 8.09%	142,465 $27.5 Million
Q2 2018 Jul 20, 2018	BUY	$145.72 - $169.96 $728,600 - $849,800	5,000 Added 3.33%	155,000 $26.3 Million
Q1 2018 Apr 11, 2018	SELL	$151.6 - $177.13 $334,126 - $390,394	-2,204 Reduced 1.45%	150,000 $24.4 Million
Q4 2017 Jan 19, 2018	SELL	$137.28 - $155.55 $3.82 Million - $4.32 Million	-27,796 Reduced 15.44%	152,204 $22.8 Million
Q3 2017 Oct 13, 2017	BUY	$148.13 - $162.24 $26.7 Million - $29.2 Million	180,000	180,000 $27.4 Million

Others Institutions Holding VRTX

# of Institutions

1,717

Shares Held

226M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $133B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

News

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.

Account

Rhenman & Partners Asset Management Ab Vertex Pharmaceuticals Inc Transaction History